September 3, 2024

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the acquisition of the royalty rights to “Thank God I Got It” by the renowned artist Desiigner. This acquisition underscores Music Licensing, Inc.’s commitment to diversifying its portfolio with high-quality, revenue-generating assets.

This strategic purchase adds to a series of recent acquisitions by Music Licensing, Inc., including musical works by iconic artists such as Elton John, Miley Cyrus, Lil Wayne, Rihanna, The Weeknd, Kanye West, Justin Bieber, Mike Posner, Halsey, & many more. These acquisitions align with the company’s strategy to invest in a broad range of musical talents and genres, enhancing its offerings and appeal to a global audience.

Jake P. Noch, CEO of Music Licensing, Inc., commented on the acquisition, “Securing the rights to ‘Thank God I Got It’ alongside works from other music industry giants significantly strengthens our portfolio and positions us for continued growth. Each of these artists brings a unique sound and fanbase, increasing the potential for robust royalty streams and enriching our company’s asset base.”

The addition of “Thank God I Got It” to Music Licensing, Inc.’s catalog is part of the company’s broader strategy to leverage high-impact musical works that promise sustainable revenue and cultural relevance. By investing in a wide array of music royalties, the company ensures a dynamic portfolio that meets the diverse tastes of the music listening public and solidifies its market position as a leader in the music industry.

Listen to “Thank God I Got It” by Desiigner here.

About Music Licensing, Inc. (OTC: SONG) (ProMusicRights.com)

Music Licensing, Inc. (OTC: SONG), also known as Pro Music Rights, is a diversified holding company and the fifth public performance rights organization (PRO) formed in the United States. Its licensees include notable companies such as TikTok, iHeart Media, Triller, Napster, 7Digital, Vevo, and many others. Pro Music Rights holds an estimated market share of 7.4% in the United States, representing over 2,500,000 works by notable artists such as A$AP Rocky, Wiz Khalifa, Pharrell, Young Jeezy, Juelz Santana, Lil Yachty, MoneyBagg Yo, Larry June, Trae Pound, Sauce Walka, Trae Tha Truth, Sosamann, Soulja Boy, Lex Luger, Trauma Tone, Lud Foe, SlowBucks, Gunplay, OG Maco, Rich The Kid, Fat Trel, Young Scooter, Nipsey Hussle, Famous Dex, Boosie Badazz, Shy Glizzy, 2 Chainz, Migos, Gucci Mane, Young Dolph, Trinidad James, Chingy, Lil Gnar, 3OhBlack, Curren$y, Fall Out Boy, Money Man, Dej Loaf, Lil Uzi Vert, and countless others, as well as artificial intelligence (A.I.) created music.

Additionally, Music Licensing, Inc. (OTC: SONG) owns royalty stakes in Listerine “Mouthwash” Antiseptic and musical works by artists such as The Weeknd, Justin Bieber, Kanye West, Elton John, Mike Posner, blackbear, Lil Nas X, Lil Yachty, DaBaby, Stunna 4 Vegas, Miley Cyrus, Lil Wayne, XXXTentacion, Jeremih, Ty Dolla $ign, Eric Bellinger, Ne-Yo, MoneyBagg Yo, Halsey, Desiigner, DaniLeigh, Rihanna, and numerous others.

Forward-Looking Statements:

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Music Licensing, Inc. & Pro Music Rights, Inc. to accomplish its stated plan of business. Music Licensing, Inc. & Pro Music Rights, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by Pro Music Rights, Inc., Music Licensing, Inc., or any other person.

Non-Legal Advice Disclosure:

This press release does not constitute legal advice, and readers are advised to seek legal counsel for any legal matters or questions related to the content herein.

Non-Investment Advice Disclosure:

This communication is intended solely for informational purposes and does not in any way imply or constitute a recommendation or solicitation for the purchase or sale of any securities, commodities, bonds, options, derivatives, or any other investment products. Any decisions related to investments should be made after thorough research and consultation with a qualified financial advisor or professional. We assume no liability for any actions taken or not taken based on the information provided in this communication.

Contact: [email protected]

SOURCE: Music Licensing, Inc

GlobeNewswire Distribution ID 9223975

September 3, 2024

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des droits d’auteur du titre « Thank God I Got It » composé par le célèbre rappeur Desiigner. Cette acquisition souligne l’engagement de Music Licensing, Inc. à agrémenter son catalogue de titres lucratifs au top.

Cet achat stratégique prend la suite d’une série de récentes acquisitions pilotées par Music Licensing, Inc., comprenant des œuvres musicales d’artistes phares comme Elton John, Miley Cyrus, Lil Wayne, Rihanna, The Weeknd, Kanye West, Justin Bieber, Mike Posner, Halsey, et bien d’autres encore. Ces acquisitions font écho à la stratégie de l’entreprise, visant à investir dans un large portefeuille de talents et de genres pour dynamiser son offre et renforcer son attractivité auprès d’un public mondial.

Jake P. Noch, PDG de Music Licensing, Inc., s’est exprimé à ce sujet : « Réussir l’obtention des droits de “Thank God I Got It” et l’annexer à notre catalogue aux côtés d’œuvres d’autres stars de l’industrie musicale renforce nettement notre gamme et joue en faveur d’une croissance continue. Tous ces artistes apportent à la fois leur signature propre et leur public, ce qui relève le plafond de nos recettes perçues par les droits d’auteur et enrichit nos actifs. »

Inclure « Thank God I Got It » au catalogue de Music Licensing, Inc. s’intègre à la stratégie de l’entreprise au sens large, reposant sur le principe de tirer parti d’œuvres musicales à fort impact, sources de revenus durables et synonymes d’un intérêt culturel. En investissant dans une large gamme de droits musicaux, l’entreprise garantit le dynamisme de son portefeuille et répond aux tendances hétéroclites des fans de musique tout en asseyant sa position de leader du marché de l’industrie musicale.

Pour écouter « Thank God I Got It » de Desiigner, cliquez ici.

À propos de Music Licensing, Inc. (OTC : SONG) (ProMusicRights.com)

Music Licensing, Inc. (OTC : SONG), également connue sous le nom de Pro Music Rights, est une société holding diversifiée et la cinquième société de droits d’auteur établie aux États-Unis. Ses licences se rapportent à des entreprises renommées comme TikTok, iHeart Media, Triller, Napster, 7Digital, Vevo, entre autres. Aux États-Unis, la part de marché de Pro Music Rights est estimée à 7,4 %, et représente plus de 2 500 000 titres mettant en vedette des artistes aussi célèbres qu’A$AP Rocky, Wiz Khalifa, Pharrell, Young Jeezy, Juelz Santana, Lil Yachty, MoneyBagg Yo, Larry June, Trae Pound, Sauce Walka, Trae Tha Truth, Sosamann, Soulja Boy, Lex Luger, Trauma Tone, Lud Foe, SlowBucks, Gunplay, OG Maco, Rich The Kid, Fat Trel, Young Scooter, Nipsey Hussle, Famous Dex, Boosie Badazz, Shy Glizzy, 2 Chainz, Migos, Gucci Mane, Young Dolph, Trinidad James, Chingy, Lil Gnar, 3OhBlack, Curren$y, Fall Out Boy, Money Man, Dej Loaf, Lil Uzi Vert, et une myriade d’autres stars, sans oublier la musique générée par l’intelligence artificielle (IA).

Music Licensing, Inc. (OTC : SONG) détient par ailleurs les droits du bain de bouche antiseptique de Listerine, ainsi que d’œuvres musicales d’artistes comme The Weeknd, Justin Bieber, Kanye West, Elton John, Mike Posner, blackbear, Lil Nas X, Lil Yachty, DaBaby, Stunna 4 Vegas, Miley Cyrus, Lil Wayne, XXXTentacion, Jeremih, Ty Dolla $ign, Eric Bellinger, Ne-Yo, MoneyBagg Yo, Halsey, Desiigner, DaniLeigh, Rihanna, et bien d’autres encore.

Déclarations prospectives :

Le présent communiqué de presse contient des déclarations prospectives au sens de l’article 27A de la loi américaine Securities Act de 1933, telle qu’amendée (loi sur les valeurs mobilières) et de l’article 21E de la loi américaine Securities Exchange Act de 1934 (loi sur les bourses de valeurs), soumises à la « sphère de sécurité » instituée par ces articles. La société met en garde les investisseurs du fait que toute déclaration prospective induit des risques et des incertitudes, y compris, sans toutefois s’y limiter, la capacité de Music Licensing, Inc. et/ou de Pro Music Rights, Inc. à réaliser le plan d’affaires qu’elle s’est fixée. Music Licensing, Inc./Pro Music Rights, Inc. estime que les hypothèses qui sous-tendent les déclarations prospectives exprimées dans le présent communiqué sont raisonnables. Néanmoins, l’une ou l’autre de ces hypothèses pourrait s’avérer inexacte et, par conséquent, rien ne garantit que les déclarations prospectives intégrées au présent communiqué de presse se révéleront exactes. Compte tenu des incertitudes majeures propres aux déclarations prospectives du présent document, l’intégration de ces informations ne saurait être considérée comme une déclaration de Pro Music Rights, Inc. et/ou de Music Licensing, Inc. ni de toute autre personne.

Déclaration relative aux conseils juridiques :

Le présent communiqué de presse ne constitue pas un conseil juridique et il est conseillé aux lecteurs de s’adresser à un conseiller juridique pour résoudre tout problème ou toute question d’ordre juridique en rapport avec le contenu du présent document.

Déclaration relative aux conseils en investissement :

Cette communication est uniquement destinée à des fins d’information et n’implique ni ne constitue en aucune manière une recommandation ou une sollicitation d’achat ou de vente de titres, de matières premières, d’obligations, d’options, de produits dérivés ou de tout autre produit d’investissement. Toute décision relative aux investissements doit être prise à l’issue d’une recherche approfondie et après consultation auprès d’un conseiller financier qualifié ou d’un professionnel de la finance. Nous déclinons toute responsabilité pour les actions prises ou non sur la base des informations fournies dans cette communication.

Contact : [email protected]

SOURCE : Music Licensing, Inc.

GlobeNewswire Distribution ID 9223976

September 3, 2024

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies.

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of the SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study for REC-994 in symptomatic CCM patients.

REC-994 met its primary endpoint of safety and tolerability, demonstrating a similar profile across placebo and both 200mg and 400mg dosage-arms with regard to the frequency and severity of adverse events after 12 months of treatment. Magnetic resonance imaging-based secondary efficacy endpoints showed a trend towards reduced lesion volume and hemosiderin ring size in patients at the highest dose (400mg) as compared to placebo. Time-dependent improvement in these trends at the 400mg dose was also observed in this signal-finding study. Improvements in either patient or physician-reported outcomes were not yet seen at the 12 month time point. A meeting with the FDA is anticipated as soon as practical to discuss plans for an additional clinical study. Recursion plans to present data from this trial at a forthcoming medical conference and intends to submit these data for publication in a peer reviewed scientific journal.

“These studies are making significant strides in the development of therapeutics for CCM. The data from this readout is an impressive start and will provide a valuable contribution to the existing CCM literature and strongly supports the need for a future study, with a longer duration and a larger patient cohort,” said Dr. Jan-Karl Burkhardt, MD, Division Head, Cerebrovascular Surgery, University of Pennsylvania and Principal Investigator of the study. Connie Lee, Psy.D., founder and CEO of the Alliance to Cure Cavernous Malformation added: “I speak for the patients who have participated in the trial and those who have been cheering from the sidelines while waiting for news. This promising start is a critical step forward and will bring hope to thousands of families who currently have no options but brain or spinal cord surgery. The Alliance to Cure Cavernous Malformation looks forward to partnering with Recursion as they move to the next stage of the REC-994 program.”

“We are encouraged by the recent data from our signal-finding Phase 2 study in CCM, where the trial successfully met its primary safety endpoint and became the first investigational therapy to demonstrate safety alongside some promising trends in exploratory efficacy endpoints. These results provide critical insights that will inform our next study design, including exploring study duration, higher doses, and a larger cohort of patients,” said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer of Recursion. “This is the first of several key clinical readouts for the company and represents an early proof-of-platform milestone for our constantly evolving Recursion OS, as we build upon our success in drug discovery with expertise and execution in mid-phase development. We are deeply grateful to the patients and investigators, and we are committed to advancing potential transformational therapies for CCM and beyond.”

Background on Cerebral Cavernous Malformation (CCM)

CCM is a neurovascular condition that impacts approximately 360,000 symptomatic individuals in the US and EU5. The disease is often underdiagnosed and potentially affects over 1 million patients worldwide. CCM manifests as vascular malformations of the spinal cord and brain characterized by abnormally enlarged capillary cavities without intervening brain parenchyma. Patients with CCM lesions are at substantial risk for seizures, headaches, progressive neurological deficits, and potentially fatal hemorrhagic stroke. Currently, only non-pharmacologic treatments including microsurgical resection and stereotactic radiosurgery are available options for this high unmet need patient population. However, surgical resection or stereotactic radiosurgery is not always feasible because of location and may not be curative.

About REC-994

REC-994 is an orally bioavailable, superoxide scavenger small molecule under development for the treatment of symptomatic CCM. The potential of REC-994 in CCM was demonstrated using the earliest version of what would become the foundational technology underlying the Recursion OS. Subsequently, REC-994 demonstrated preclinical activity in models for CCM and tolerability and suitability for chronic dosing in Phase 1 single ascending dose escalation (SAD) and multiple ascending dose escalation (MAD) trials in healthy volunteers directed and executed by Recursion. Recursion has sought and received Orphan Drug Designation for REC-994 in symptomatic CCM in the US and Europe.

About the Trial

Our Phase 2 SYCAMORE clinical trial is a randomized, double-blind, placebo-controlled study of two doses of REC-994 in participants with CCM. The primary endpoint of the study is safety and tolerability. Secondary efficacy endpoints include MRI-based endpoints, clinician and patient reported outcomes, as well as selected biomarkers. This trial was fully enrolled in June 2023 with 62 participants, and 80% of participants who completed 12 months of treatment have entered the long-term extension study. This signal-finding study was not powered to demonstrate statistical significance.

About Recursion

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
[email protected]

Investor Contact
[email protected]

Forward-Looking Statements

This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion’s anticipated meeting with the FDA; Recursion’s plans to present SYCAMORE trial data at a medical conference and submit the data for publication; the clinical relevance of the SYCAMORE trial data and obtaining additional confirmatory data; promising trends in REC-994 efficacy endpoints; advancing potential transformational therapies for CCM and beyond; subsequent REC-994 studies and their results and advancing Recursion’s REC-994 program further; the size of the potential CCM patient population; Recursion OS and other technologies potential and advancement of the future of medicine; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, our subsequent Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

GlobeNewswire Distribution ID 9223929

September 3, 2024

Deriv Celebrates 25th Anniversary with “UK’s Best Workplaces in Financial Services & Insurance™” Win

Deriv’s UK team celebrates the Best Place to Work win

Deriv’s UK employees pose for their first group photo celebrating the Best Place to Work win and renewal of their GPTW accreditation.

UK office has also received a renewal for its Great Place to Work^® certifications alongside six other Deriv offices
Celebrates 25 years of building a positive workplace culture

Deriv’s UK team celebrates the Best Place to Work win

LONDON, Sept. 03, 2024 (GLOBE NEWSWIRE) — Deriv, a leading online trading platform celebrating 25 years of innovation and service, has been recognised as one of the “UK’s Best Workplaces in Financial Services & Insurance” for 2024. This prestigious award underscores Deriv’s commitment to upholding a workplace culture rooted in trust, innovation, and exceptional service.

In addition to this remarkable achievement, Deriv’s UK offices have also renewed their Great Place to Work^® certifications alongside six other offices (Paraguay, Cyprus, France, Jordan, Malta, and Rwanda), with Deriv Paraguay being re-certified for the third year in a row. This further highlights the company’s dedication to creating a positive and fulfilling work environment across its global operations.

“We are incredibly honoured to receive this recognition, especially since people have been the heart of our business for 25 years,” said Seema Hallon, Chief Human Resources Officer. “It exemplifies the hard work and passion of our entire team, who consistently strive to create an environment where everyone feels valued, empowered, and inspired to reach their full potential. These awards not only celebrate our past achievements, they reinforce our belief that a strong workplace culture is the cornerstone of long-term success and sets the stage for the next 25 years of Deriv.”

Deriv’s latest win highlights the company’s core values, which have been instrumental in its success over the past 25 years and will continue to shape its future.

Trust: Deriv cultivates a culture of transparency, open communication, and mutual respect, ensuring employees feel confident and secure in their work environment.
Innovation: The company encourages creativity, experimentation, and continuous learning, enabling employees to develop advanced solutions that meet the evolving needs of traders worldwide.
Service: Deriv is passionate about providing exceptional customer service and equipping traders with the tools and resources they need to thrive in the financial markets.

Benedict Gautrey, Managing Director of Great Place To Work^® UK said:

“The  Best Workplaces  in Financial Services and Insurance list is created using the anonymous feedback from employees working in the industry about their workplace experience.

Benchmarking yourself against others in the industry, by surveying your people to understand how your culture compares to others, helps leaders not only make better informed decisions on areas for improvement, but also gives employers a data-based understanding of what aspects of their current offering makes them stand out, helping to build a more competitive employer brand.

It’s great to see so many examples of organisations making their workplaces truly ‘great’. A huge congratulations to Deriv for making this prestigious list.”

“We will continue to invest in our people and an environment where trust, innovation, and service flourish,” added Hallon. “It’s our exceptional team that will drive Deriv’s continued growth and innovation in the industry and keep it a great place to work for years to come.”

About Deriv

For 25 years, Deriv has been committed to making online trading accessible to anyone, anywhere. Trusted by over 2.5 million traders worldwide, the company offers an expansive range of trade types and boasts over 200 assets across popular markets on award-winning, intuitive trading platforms. With a workforce of more than 1,400 people globally, Deriv has cultivated an environment that celebrates achievements, encourages professional growth, and nurtures talent development, which is reflected in its Platinum accreditation by Investors in People.

Press contact
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/64460c21-fdc6-4075-a7a5-0b2b3efcbf17

GlobeNewswire Distribution ID 9224195

September 3, 2024

Deriv célèbre son 25e anniversaire avec la récompense “UK’s Best Workplaces in Financial Services & Insurance™”

L’équipe de Deriv basée au Royaume-Uni célèbre la récompense Best Place to Work

Première photo de groupe de l’équipe de Deriv basée au Royaume-Uni pour célébrer la récompense Best Place to Work et son accréditation Great Place To Work renouvelée.

Deriv a également renouvelé les certifications Great Place to Work de ses bureaux basés au Royaume-Uni et dans six autres pays
Célèbre 25 années passées à créer une culture d’entreprise positive

L’équipe de Deriv basée au Royaume-Uni célèbre la récompense Best Place to Work

LONDRES, Royaume-Uni, 03 sept. 2024 (GLOBE NEWSWIRE) — Deriv, une plateforme de trading en ligne de premier plan qui célèbre 25 ans d’innovation et de service, a reçu la distinction du “UK’s Best Workplaces in Financial Services & Insurance” en 2024. Cette prestigieuse distinction souligne l’engagement de Deriv pour ce qui est de maintenir une culture d’entreprise axée sur la confiance, l’innovation et le service exceptionnel.

Outre cet accomplissement remarquable, Deriv a également renouvelé les certifications Great Place to Work^® de ses bureaux basés au Royaume-Uni et dans six autres pays (Paraguay, Chypre, France, Jordanie, Malte et Rwanda), les bureaux du Paraguay obtenant cette certification pour la troisième année consécutive. Cela souligne davantage la volonté de l’entreprise de créer un environnement de travail positif et épanouissant dans toutes ses activités au plan mondial.

« C’est un honneur inestimable pour nous de recevoir une telle reconnaissance, et ce bien plus parce que depuis 25 ans, les personnes sont au cœur de notre activité », a déclaré Seema Hallon, directrice des Ressources humaines. « C’est une preuve du travail acharné et de la passion qui animent toute notre équipe, laquelle œuvre en continu pour créer un environnement qui valorise, autonomise et inspire chacun afin qu’il réalise son plein potentiel. Ces distinctions ne célèbrent pas seulement nos réalisations antérieures, mais elles renforcent également notre certitude qu’une culture d’entreprise forte assure une réussite à long terme et jalonne les 25 prochaines années de Deriv. »

Les récentes récompenses de Deriv mettent en avant les principales valeurs de l’entreprise, lesquelles lui ont permis de faire florès au cours des 25 dernières années et continueront d’ailleurs de façonner son futur.

Confiance : Deriv entretient une culture de transparence, de communication ouverte et de respect mutuel, ce qui alimente le sentiment de confiance et de sécurité des employés dans leur environnement de travail.
Innovation : L’entreprise encourage la créativité, l’expérimentation et l’apprentissage continu, permettant ainsi aux employés de développer des solutions de pointe qui répondent aux besoins de traders du monde entier.
Service : Fournir un service client exceptionnel et doter les traders d’outils et de ressources dont ils ont besoin pour s’épanouir sur les marchés financiers est la raison d’être de Deriv.

Benedict Gautrey, directeur de Great Place To Work^® au Royaume-Uni a déclaré :

« La liste des nominés au Best Workplaces in Financial Services and Insurance est créée sur la base des retours sur l’expérience de travail d’employés travaillant dans le secteur.

S’auto-évaluer par rapport à d’autres concurrents, grâce à un sondage de son personnel pour évaluer sa culture par rapport à d’autres, permet non seulement aux décideurs de prendre de meilleures décisions quant aux points à améliorer, mais offre également aux employeurs une compréhension basée sur les données des aspects de leurs offres actuelles qui les distinguent, leur permettant ainsi de créer une image d’entreprise plus concurrentielle.

Il est plaisant de voir autant d’organisations s’atteler à rendre leur lieu de travail vraiment épanouissant. »

« Nous continuerons d’investir dans notre personnel et à rendre leur environnement propice à la confiance, à l’innovation et au service. », a ajouté Hallon. « Notre équipe exceptionnelle continuera de favoriser la croissance continue et l’innovation de Deriv dans le secteur et d’en faire un lieu de travail épanouissant dans les années à venir. »

À propos de Deriv

Depuis 25 ans, Deriv s’attèle à rendre le trading en ligne accessible à tous et partout. Constituée aujourd’hui de plus de 2,5 millions de traders dans le monde, Deriv fournit une riche gamme de types de contrat. En outre, elle propose fièrement plus de 200 actifs sur des marchés populaires à partir de ses plateformes de trading primées et intuitives. Deriv a su développer une culture au sein de ses bureaux, comptant plus de 1 400 employés répartis dans le monde, qui célèbre les réalisations, encourage la croissance professionnelle et favorise le développement des talents, ce qui justifie son accréditation Platinum délivrée par Investors in People.

Contact presse
[email protected]

Une photo accompagnant ce communiqué est disponible au : https://www.globenewswire.com/NewsRoom/AttachmentNg/64460c21-fdc6-4075-a7a5-0b2b3efcbf17/fr

GlobeNewswire Distribution ID 9224195

September 3, 2024

NamPower chairperson resigns

WINDHOEK: The Namibia Power Corporation ( NamPower ) Board on Tuesday announced that Ester Kali has resigned as its chairperson , effective 31 August 2024 , in line with regulatory requirements . In a media statement , the board stated that Minister of Finance and Public Enterprises , Iipumbu Shiimi appointed Clive Kavendjii as acting chairperson until a permanent successor is appointed . ‘ The NamPower Board and Management wholeheartedly appreciate the leadership and opportunity to have worked with Dr Kali and wish her all the best . In addition , we look forward to the stewardship of the Board under the able leadership of Mr Kavendjii ,’ it said .

Source:The Namibia News Agency